ampakines


Also found in: Wikipedia.

ampakines

A class of drugs that act on nerve cell receptors to make them more responsive to the NEUROTRANSMITTER glutamate. Ampakines alter the ways in which a memory is encoded and modify the strength of the memory trace. A few small clinical trials have suggested that ampakines can significantly improve memory in elderly people. The duration of action is short.
References in periodicals archive ?
Studies of cells in the laboratory have shown that drugs called ampakines elevate production of BDNF.
Ampakines are designed to compensate for deterioration of AMPA-receptor mediated brain activity in patients with Alzheimer's and other disorders.
ONE US company has been working on a class of drugs called ampakines.
The drugs - called ampakines - work by boosting the levels of a brain chemical that makes it easier to learn and create memoriesDr Gary Lynch, who discovered the drug, explained: 'We all have the same computer but we're running with different voltage levels.
This brings our total portfolio on the AMPAKINEs to 17 issued and allowed patents, with 58 additional patent applications in various stages of review throughout the world.
Greer stated, "It is striking how well AMPAKINES enhance the activity of brain cells in the respiratory rhythm generator.
A patent entitled, "Treatment of Schizophrenia with AMPAKINEs and Neuroleptics" recently issued in Australia under patent No.
Research conducted at the University of California, Irvine (Irvine, CA) demonstrates that AMPAKINEs can increase the production of the important neurotrophic factors BDNF (brain derived neurotrophic factor) and NGF (neuronal growth factor) in critical areas of the brain involved in memory.
AMPAKINES could one day allow for improved safety and a more effective use of opiate analgesics and barbiturate sedatives, two important classes of central nervous system drugs.
Amex: COR) today announced it has been notified that the National Institutes of Mental Health (NIMH) will fund the Company's grant application, "Therapeutic Potential of AMPAKINEs in Schizophrenia.
In November 1998, scientists from University of California, Irvine and Cortex presented data at the Society for Neuroscience in Los Angeles regarding the enhancement of neurotrophic factor expression by AMPAKINES.
AMPAKINES were mentioned in the December 6, 2004 Newsweek cover story, "The Quest for Memory Drugs".